StreetInsider.com News Articles

Form 4 Oruka Therapeutics, Inc. For: Jun 11 Filed by: Dambkowski Carl

Fri, 12 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260612/26641489.html

Form 4 Oruka Therapeutics, Inc. For: Jun 11 Filed by: Dambkowski Carl

Fri, 12 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260612/26641489.html

Form 144 Oruka Therapeutics, Inc. Filed by: Dambkowski Carl

Thu, 11 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260611/26636040.html

Form 144 Oruka Therapeutics, Inc. Filed by: Dambkowski Carl

Thu, 11 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260611/26636040.html

Form 8-K Oruka Therapeutics, Inc. For: Jun 02

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605928.html

Form 8-K Oruka Therapeutics, Inc. For: Jun 02

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605928.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Dambkowski Carl

Wed, 03 Jun 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260603/26599921.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Dambkowski Carl

Wed, 03 Jun 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260603/26599921.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Kulkarni Samarth

Wed, 03 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26599902.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Kulkarni Samarth

Wed, 03 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26599902.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Martin Christopher Nathan

Wed, 03 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260603/26599883.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Martin Christopher Nathan

Wed, 03 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260603/26599883.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: BALL KRISTINE M

Wed, 03 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260603/26599871.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: BALL KRISTINE M

Wed, 03 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260603/26599871.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Fairmount Funds Management LLC

Wed, 03 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260603/26599821.html

Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Fairmount Funds Management LLC

Wed, 03 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260603/26599821.html

H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)

Wed, 03 Jun 2026 06:51:42 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $120.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: "On May 29, 2026, Oruka Therapeutics entered into the first amendment to the IL-23 license agreement dated as of December 17, 2024, by and between Oruka and privately-held Paragon Therapeutics, Inc. Prior to the amendment, the field of potential development for Oruka did not include inflammatory bowel disease (IBD). The amendment, among other things, expands the definition of “field” to encompass all therapeutic, prophylactic, palliative and diagnostic uses, subject to the restriction that the company will not dose a

Piper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'

Tue, 02 Jun 2026 08:26:33 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: "ORKA-001 License Amendment Enables Future IBD Dev. Boosting Long-Term Value; ORKA filed an 8-K detailing an amendment to its license agreement with Paragon Therapeutics (private). Altogether, this effectively "freed up" indication rights to the IL-23s for both ORKA and SYRE (not covered), and enables combination/monotherapy development in previously restricted areas after a 2-4-year delay. For instance, ORKA will eventually be allowed to pursue IBD (SYRE will eventually be able to develop in PsO/PsA). Ultimately, ORKA explained that serves two key

Oruka Therapeutics expands license agreement to include IBD indication

Mon, 01 Jun 2026 16:05:22 -0400

Oruka Therapeutics Inc. (NASDAQ: ORKA) amended its IL-23 license agreement with Paragon Therapeutics Inc. on May 29, 2026, expanding the therapeutic field to include inflammatory bowel disease.

The amendment modifies the original license agreement dated December 17, 2024, broadening the definition of "Field" to encompass all therapeutic, prophylactic, palliative and diagnostic uses. The expanded rights come with timing restrictions on clinical development for inflammatory bowel disease applications.

Under the amended terms, Oruka cannot dose human patients in clinical trials of ORKA-001 for inflammatory bowel disease as part of a combination therapy until June 1, 2028, or as monotherapy until June 1, 2030.

The

Form 8-K Oruka Therapeutics, Inc. For: May 29

Mon, 01 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260601/26583339.html

Form 8-K Oruka Therapeutics, Inc. For: May 29

Mon, 01 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260601/26583339.html

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

Thu, 28 May 2026 08:35:00 -0400

DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

That is why so much attention is focused on companies that are approaching

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

Thu, 28 May 2026 08:35:00 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

That is why so much attention is focused on companies that are approaching

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

Thu, 28 May 2026 08:35:00 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

That is why so much attention is focused on companies that are approaching

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

Thu, 28 May 2026 08:35:00 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

That is why so much attention is focused on companies that are approaching